A/APublished research associates this genotype with typical/baseline likelihood of Heart rate response to beta blockers (atenolol add-on therapy) — no copies of the reported risk allele.
A/TPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Heart rate response to beta blockers (atenolol add-on therapy).
T/TPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Heart rate response to beta blockers (atenolol add-on therapy) compared to the general population.
Journal of the American Heart Association · 2018 · PMID 29478026 · open access
Questions about rs17044630
What is rs17044630?
rs17044630 is a single position in the genome, in or near the MARCHF1 gene. Published research associates it with heart rate response to beta blockers (atenolol add-on therapy). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
What conditions is rs17044630 linked to?
On MyGeneLog this position is linked to Heart Rate Response to Beta Blockers. The research behind each link, and its sources, are set out on that condition page.
Does having rs17044630 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs17044630 come from?
GWAS Catalog, J Am Heart Assoc 2018, PMID:29478026. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.